Austin Schwartz, Director of Operations
March 11th, 2020
Tellus Therapeutics is on target for a productive 2020 and is gaining traction towards its mission of developing treatments for unmet needs in newborns. Support from the MassChallenge 2019 Diamond Award ($100,000) has allowed Tellus to further strengthen operations and advance development of its lead asset, TT-20, and the company’s pipeline development program. IND-enabling studies funded by a Duke Clinical and Science Translational Institute (CTSI) Grant ($500,000) are underway while the CMC program and regulatory interactions are supported by a Small Business Research Loan ($250,000) from the North Carolina Biotechnology Center (NCBC) and a pending SBIR application. Tellus will prepare applications for Orphan and Rare Pediatric designations and further engage the FDA in a pre-IND meeting within the next year. Development of Tellus’ clinical trial strategy continues with engagement of expertise across Duke and Harvard’s Boston Children’s and Brigham and Women’s Hospitals.
Concurrent with these efforts, Tellus intends to seek additional financing to complete IND-enabling studies, conduct a Phase 1b clinical trial for TT-20, continue pipeline development and support company operations.
This company announcement is for informational purposes only and is neither an offer to sell securities nor a solicitation for investment in Tellus Therapeutics. Any such offer or solicitation will be made solely through definitive offering documents (identified as such) that will contain material information about Tellus Therapeutics, the terms and conditions of an investment and may also describe risks related to an investment in Tellus Therapeutics, and such materials will qualify in its entirety the information set forth in this company announcement.